{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-25-000030","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.479086+00:00","generated_at":"2026-05-17T21:28:19.069621+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inspire Medical Q2 net loss $3.6M, cuts FY 2025 revenue guidance to $900-910M","bullets":["Q2 revenue $217.1M (+11% YoY), net loss $3.6M vs prior year net income $9.8M.","Adjusted diluted EPS $0.45; GAAP diluted loss per share $0.12.","FY 2025 revenue guidance cut to $900-910M (prior $940-955M); EPS cut to $0.40-0.50 from $2.20-2.30.","Full U.S. launch of Inspire V neurostimulation system initiated.","EVP Randall Ban to retire on January 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-25-000030","json":"https://secwatch.observer/filing/0001609550-25-000030.json","markdown":"https://secwatch.observer/filing/0001609550-25-000030.md","text":"https://secwatch.observer/filing/0001609550-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000030/0001609550-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955025000030/insp-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:28:19.069621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}